Position in REVB
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$387,889
+$40,472 QoQ
Shares Held
323,241
-25.6% QoQ
Ownership
8.11%
of shares outstanding
% of Portfolio
0.01%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Sep 2025
3 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in REVB Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026ARMISTICE CAPITAL, LLC holds $1,358,853,063 across 56 Biotechnology names. REVB ranks #46 (0.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | TVTX |
Travere Therapeutics, Inc.
|
4,897,417 | $145,502,259 | |
| 2 | PTCT |
Ptc Therapeutics, Inc.
|
2,074,449 | $141,332,210 | |
| 3 | MDGL |
Madrigal Pharmaceuticals, Inc.
|
264,583 | $138,501,263 | |
| 4 | AGIO |
Agios Pharmaceuticals, Inc.
|
2,716,000 | $91,882,280 | |
| 5 | IMVT |
Immunovant, Inc.
|
3,564,916 | $88,552,513 | |
| 6 | INCY |
Incyte Corp
|
656,817 | $61,819,616 | |
| 7 | DYN |
Dyne Therapeutics, Inc.
|
3,175,110 | $57,564,744 | |
| 8 | CYTK |
Cytokinetics Inc
|
764,538 | $50,390,699 |
All Filings in REVB
Export CSV
4 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $387,889 | 323,241 | Shares | Sole | 2026-05-15 | |
| 2026-03-31 | $387,889 | 323,241 | Shares | Sole | 2026-05-15 | |
| 2025-12-31 | $347,417 | 434,272 | Shares | Sole | 2026-02-17 | |
| 2025-09-30 | $113,600 | 80,000 | Shares | Sole | 2025-11-17 | |
| No filing history on record for this holder in this stock. | ||||||